Among these compounds, the IL-6 receptor (IL-6R) inhibitor tocilizumab (TCZ) has been effective in several randomized clinical trials (RCT) in Stage 2b-3 COVID-19 [11,12,13,14]. The gene discussed is IL6R; the disease is COVID-19.